Day: June 26, 2024

– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD reinforces potential as a sustained six-month maintenance therapy – – Phase 2 trial of DURAVYU in diabetic macular edema (DME) fully enrolled – – EyePoint to webcast its R&D Day event today at 8:00 a.m. ET – WATERTOWN, Mass., June 26, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced the Company will highlight clinical and regulatory developments...

Sole Source Contract will lead to further growth with the US GovernmentOPT WAM-VImage of OPT’s WAM-V USV.MONROE TOWNSHIP, N.J., June 26, 2024 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced it has reached an agreement in principle on a sole source contract award for multiple WAM-Vs for delivery to a Department of the US Government. The final contract award will be a Firm-Fixed-Price purchase order on a noncompetitive basis. Revenue will be recognized ratably over the course of the contract with an expected near-term delivery date. Due to the sensitive nature of this relationship, terms have not been disclosed. This award builds on the recent commercial...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION INTHE UNITED STATES OR TO U.S. NEWS AGENCIES HONG KONG, June 26, 2024 (GLOBE NEWSWIRE) — Century Global Commodities Corporation (“Century” or the “Company”) (TSX: CNT) is pleased to announce that it has filed its audited consolidated financial statements for the year ended March 31, 2024 and the related management discussion and analysis (“MD&A”) as well as the Annual Information Form. Copies of these documents are available under Century’s SEDAR+ profile at http://www.sedarplus.ca and will also be posted on Century’s website at www.centuryglobal.ca. As of March 31, 2024, the Company had net working capital* of $6.1 million, consisting of unrestricted free cash, bank deposits and marketable securities totaling $5.0 million, together with accounts receivables, inventories and other...

ESTERO, Fla., June 26, 2024 (GLOBE NEWSWIRE) — via IBN — GRN Holding Corporation, (OTC: GRNF) is proud to announce its strategic rebranding to Marijuana Inc. (www.marijuanainc.com) to signal a new era of growth and innovation in the global cannabis industry. This transformation is led by the renowned CEO, Donald Steinberg, whose illustrious career in the marijuana sector spans over five decades. Donald Steinberg: Recognized as the “Henry Ford of the Marijuana Industry.” Donald Steinberg, documented in multiple books for his pioneering efforts in the marijuana industry, has a storied history that sets him apart from all others in the field. In the 1980s, Steinberg was recognized by Centac, a U.S. government agency, as the largest importer of marijuana into the United States in the 1970s and the largest U.S. distributor....

Top line data to be reported in the second half of 2024 TEL AVIV, Israel, June 26, 2024 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced a major milestone on the way to registration – the successful completion of patient enrollment in its Phase 3 clinical trial for PRF-110, a novel analgesic drug candidate designed for the treatment of post-operative pain. In total, 428 patients have been enrolled at eight clinical sites across the U.S. As the study pain score is being tracked for 72 hours, the end of enrollment is generally the end of the clinical part of the study. The Phase 3 trial, a randomized, double-blind, placebo-controlled study, is designed...

TORONTO, June 26, 2024 (GLOBE NEWSWIRE) — Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR), today announced that the Toronto Stock Exchange (the “TSX”) has approved the Company’s notice of intention to renew its normal course issuer bid (the “NCIB”) for common shares of the Company (the “Common Shares”). Pursuant to the NCIB, the Company may purchase for cancellation up to 4,982,824 Common Shares, representing approximately 10% of the Company’s public float as at June 14, 2024. As at the date hereof, the Company has 66,372,274 Common Shares issued and outstanding. The NCIB will commence on June 28, 2024 and terminate one year after its commencement, or earlier if the maximum is reached or the NCIB is terminated at the option of the Company. The Company believes that using the NCIB to return capital to its shareholders will increase...

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024. Mr. Dulac is a highly accomplished biotechnology business leader and joins Intellia with more than 20 years of combined finance, business development and corporate strategy experience. Most recently, Mr. Dulac served as CFO of Fate Therapeutics. Prior to that role, Mr. Dulac spent numerous years at Celgene (now Bristol Myers Squibb), a leading global biopharmaceutical company, where he held...

GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the Company’s Chief Financial Officer, passed away unexpectedly on Monday, June 24, 2024. “We are all shocked and saddened by Rich’s passing. On behalf of everyone at Altimmune, I extend our heartfelt condolences to his family during this difficult time,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “Rich was not only a brilliant and dedicated leader, but a close friend who brought a sense of wit and joy to our workplace that will be dearly missed by all who had the privilege of working with him. His unique blend of hard work and humor, along with his immeasurable contributions to our Company will continue to inspire us.” Mr. Eisenstadt’s...